[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 12730
1. Javed Ali M, Honavar S: Ophthalmic disorders in adult lymphoma patients. Middle East Afr J Ophthalmol; 2010 Oct;17(4):390

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic disorders in adult lymphoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180448.001).
  • [ISSN] 0975-1599
  • [Journal-full-title] Middle East African journal of ophthalmology
  • [ISO-abbreviation] Middle East Afr J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2991465
  •  go-up   go-down


2. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Diviné M, Brice P: Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer; 2010 Feb 1;116(3):631-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
  • BACKGROUND: Nodular, lymphocyte-predominant Hodgkin lymphoma (NLPHL) represents a rare entity.
  • To determine the histologic transformation (HT) rate to diffuse large B-cell lymphoma (DLBCL) and long-term outcomes, 164 patients were selected after histologic review.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Female. Humans. Longitudinal Studies. Lymphoma / classification. Lymphoma / pathology. Male. Middle Aged. Recurrence. Time Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Cancer Society.
  • (PMID = 20029973.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N: Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer; 2009 Oct 1;115(19):4540-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
  • The authors conducted a randomized phase 2 trial of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with the addition of bortezomib in patients with B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Lymphoma, B-Cell / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. Bortezomib. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Rituximab. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 American Cancer Society.
  • (PMID = 19593797.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Boronic Acids; 0 / Pyrazines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 69G8BD63PP / Bortezomib; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


Advertisement
4. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M: Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer; 2009 Sep 15;125(6):1479-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica.
  • We evaluated whether risk of non-Hodgkin lymphoma (NHL), particularly adult T-cell leukemia/lymphoma (ATL) related to human T-lymphotropic virus (HTLV) infection was associated with 63 single nucleotide polymorphisms (SNPs) from 38 candidate genes.
  • [MeSH-major] HTLV-I Infections / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genetic Predisposition to Disease. Human T-lymphotropic virus 1 / immunology. Humans. Interleukin-13 / genetics. Interleukin-5 / genetics. Jamaica / epidemiology. Male. Middle Aged. Vascular Cell Adhesion Molecule-1 / genetics. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19533685.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL5 protein, human; 0 / Interleukin-13; 0 / Interleukin-5; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


5. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS: Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol; 2009 Jan;144(1):24-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.
  • Lymphoma is the most common malignancy among adolescents, accounting for >25% of newly diagnosed cancers in the 15-19 year age group.
  • Hodgkin lymphoma (HL) accounts for the majority (two-thirds) of cases, while the remainder of patients have one of four subtypes of non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) including primary mediastinal B-cell lymphoma (PMBL), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) or anaplastic large cell lymphoma (ALCL).
  • Adolescent lymphoma is particularly interesting because it often shares features with both childhood and adult lymphoma.
  • This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Humans. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087093.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 115
  •  go-up   go-down


6. Nitsu N, Okamoto M, Miura I, Hirano M: Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci; 2009 Feb;100(2):233-7
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) has heterogeneous clinical, histological, and molecular features.
  • A total of 1864 consecutive patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group from 1998 to 2005.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038003.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


7. Omoti AE, Omoti CE, Momoh RO: Ophthalmic disorders in adult lymphoma patients in Africa. Middle East Afr J Ophthalmol; 2009 Oct;16(4):252-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic disorders in adult lymphoma patients in Africa.
  • CONTEXT: Ocular manifestations of lymphoma are rare events.
  • Most reports of ocular involvement in lymphoma are case reports or reports of a few patients.
  • AIMS: To determine the ophthalmic disorders in adult, African, lymphoma patients.
  • SETTINGS AND DESIGN: A prospective study of ocular disorders in adult patients with lymphoma was conducted at the University of Benin Teaching Hospital, Benin City, Nigeria, between July 2004 and June 2007.
  • Of these, 51(82.3%) were non-Hodgkin's lymphoma and 11(17.7%) were Hodgkin's lymphoma.
  • Ocular disorders occurred in 16 patients (31.4%) with non-Hodgkin's lymphoma and none of the patients with Hodgkin's lymphoma (Mann-Whitney U-statistic is equal to 7.500, U' is equal to161.50, P< 0.0001).
  • The ocular disorders due to non-Hodgkin's lymphoma were seen as - proptosis in six patients (11.8%), retinopathies in three (5.9%), conjunctival infiltration in three (5.9%), optic atrophy in two (3.9%), keratoconjunctivitis in one (two per cent), desquamating nodular lid lesions in one (two per cent), papilloedema in one (two per cent), and upper lid mass in one (two per cent).
  • CONCLUSIONS: Ophthalmic disorders are relatively common in non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 1997 Apr;74(4):163-8 [9174543.001]
  • [Cites] Ophthalmology. 1999 Jul;106(7):1339-44 [10406618.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1717-22 [12208722.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ann Afr Med. 2007 Sep;6(3):89-93 [18240494.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 May;221(5):401-3 [15162291.001]
  • [Cites] Med J Malaysia. 2003 Oct;58(4):546-55 [15190631.001]
  • [Cites] Klin Oczna. 2004;106(6):783-7 [15787182.001]
  • [Cites] Clin Lab Haematol. 2005 Oct;27(5):302-6 [16178909.001]
  • [Cites] Can J Ophthalmol. 2005 Oct;40(5):623-6 [16391629.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1057-60 [12750114.001]
  • (PMID = 20404992.001).
  • [ISSN] 0975-1599
  • [Journal-full-title] Middle East African journal of ophthalmology
  • [ISO-abbreviation] Middle East Afr J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2855666
  • [Keywords] NOTNLM ; Lymphoma / Ophthalmic Disorders / Proptosis
  •  go-up   go-down


8. Roulland S, Navarro JM, Grenot P, Milili M, Agopian J, Montpellier B, Gauduchon P, Lebailly P, Schiff C, Nadel B: Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J Exp Med; 2006 Oct 30;203(11):2425-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis.
  • Follicular lymphoma is one of the most common adult lymphoma, and remains virtually incurable despite its relatively indolent nature. t(14;18)(q32;q21) translocation, the genetic hallmark and early initiating event of follicular lymphoma (FL) pathogenesis, is also present at low frequency in the peripheral blood of healthy individuals.
  • These findings strongly impact both on the current understanding of disease progression and on the proper handling of t(14;18) frequency in blood as a potential early biomarker for lymphoma.
  • [MeSH-major] B-Lymphocyte Subsets / pathology. Cell Transformation, Neoplastic / pathology. Lymphoma, Follicular / immunology. Lymphoma, Follicular / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Mar 15;99(6):2192-8 [11877297.001]
  • [Cites] Blood. 2002 May 1;99(9):3376-82 [11964306.001]
  • [Cites] Science. 2002 Dec 13;298(5601):2199-202 [12481138.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):695-8 [12640675.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3520-9 [10828038.001]
  • [Cites] J Exp Med. 2003 Apr 7;197(7):939-45 [12682112.001]
  • [Cites] Blood. 2003 May 1;101(9):3574-80 [12511417.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1196-201 [12689948.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2276-83 [14630790.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2264-9 [15026372.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):541-52 [15229473.001]
  • [Cites] Cell. 2004 Aug 20;118(4):431-8 [15315756.001]
  • [Cites] Cell. 1989 Apr 7;57(1):79-88 [2649247.001]
  • [Cites] Nature. 1991 Jan 17;349(6306):254-6 [1987477.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):1137-48 [1402658.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 May 1;85(9):2528-36 [7727781.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1333-44 [8648392.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jan;21(1):17-29 [9443038.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2871-8 [9763572.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1679-89 [9802980.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3647-54 [15191950.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1656-62 [15973453.001]
  • [Cites] Nat Rev Immunol. 2005 Nov;5(11):853-65 [16261173.001]
  • [Cites] J Clin Invest. 2006 Feb;116(2):322-33 [16424938.001]
  • [Cites] Nature. 2006 Mar 2;440(7080):105-9 [16400328.001]
  • [Cites] Leukemia. 2006 Jan;20(1):158-62 [16307019.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1363-9 [16621961.001]
  • [ErratumIn] J Exp Med. 2006 Oct 30;203(11):2563
  • (PMID = 17043145.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2118129
  •  go-up   go-down


9. Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M: Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol; 2010 Oct;21(10):2069-74
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
  • BACKGROUND: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10% of DLBCLs, and it is associated with poor prognosis.
  • PATIENTS AND METHODS: The subjects were 607 DLBCL patients in whom cell surface markers could be analyzed, among 930 consecutive patients registered in the Adult Lymphoma Treatment Study Group between 1998 and 2008.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231297.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD5; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


10. Niitsu N, Okamoto M, Miura I, Hirano M: Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia; 2009 Apr;23(4):777-83
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
  • Diffuse large B-cell lymphoma (DLBCL) having both t(14;18) and 8q24 translocations is rare.
  • A total of 1972 patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group (ALTSG) from 1998 to 2007.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic
  • [MeSH-minor] B-Lymphocytes / pathology. Bone Marrow / pathology. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase. Lymphoma, Non-Hodgkin. Male. Middle Aged. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151788.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


11. Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jürgens H, Schober O, Franzius C: Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin; 2005 Feb;44(1):1-7
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging in childhood lymphoma: differences between FDG-PET and CT.
  • AIM: The clinical value of positron emission tomography using fluorine-18 fluoro-deoxy-glucose (FDG-PET) in the staging of adult lymphoma has been shown in many studies.
  • However, there are only few data regarding childhood lymphoma.
  • The purpose of this retrospective study was to compare the staging of childhood lymphoma using FDG-PET and the established computed tomography (CT).
  • METHOD: Whole-body FDG-PET was performed in 25 children with histologically proven Hodgkin's disease (n = 18) and non-Hodgkin's lymphoma (n = 7) using a dedicated PET.
  • CONCLUSION: Staging of childhood lymphoma using FDGPET shows differences compared with CT resulting in a different staging in 6 of 25 patients.
  • [MeSH-major] Hodgkin Disease / radiography. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Fluorodeoxyglucose F18. Humans. Male. Neoplasm Staging. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711722.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Caces DD, Halaas J, Hamlin P, Noy A, Kewalramani T, Portlock CS, Zelenetz AD, O'Connor OA, Gerecitano JF: Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma.
  • : e19554 Background: Multiple reports corroborate a role for irinotecan in the treatment of lymphoma.
  • This study describes the Memorial Sloan Kettering experience with single-agent irinotecan in the management of heavily pretreated and highly refractory cases of lymphoma.
  • METHODS: Adult patients with histologically diagnosed relapsed or refractory lymphoma treated with irinotecan between 1/2001 and 8/2008 were identified.
  • Treatment responses were evaluated based on the Revised Response Criteria for Malignant Lymphoma.
  • 4 patients had Hodgkin Lymphoma (HL) and 26 had Non-Hodgkin lymphoma (NHL): 17 DLBCL, 6 transformed follicular lymphoma, 1 mantle cell lymphoma, 1 T-cell lymphoma and 1 Burkitt's. 25 patients were evaluable for response.
  • CONCLUSIONS: Irinotecan has utility even in multiply treated and highly refractory cases of lymphoma.
  • Strategies that limit adverse reactions may enhance the agent's effectiveness in refractory lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chen B, Mahmud F, Mangel J, Vujovic O, Rieder M, Zelcer S: Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation. J Clin Oncol; 2009 May 20;27(15_suppl):e19526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired endothelial function in Hodgkin lymphoma survivors receiving mediastinal radiation.
  • : e19526 Background: Mediastinal radiation (RT) is a cause of premature coronary artery disease (CAD) in Hodgkin lymphoma survivors (HLS).
  • These differences were not explained by alterations in lipoproteins or hsCRP, however activity scores were significantly lower in HLS compared with young adult controls (2.01 ± 1.1 vs. 3.6 ± 1.2 hrs daily, p=0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960923.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Beltran BE, Morales D, Quiñones P, Salas R, Castillo J: Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma.
  • : 8575 Background: Adult T-cell leukemia/lymphoma (ATLL) is associated with human T-cell lymphotropic virus type-I (HTLV-1) described in Southern Japan, Europe, Caribbean and South America.
  • The prognostic index for T-cell lymphoma (PIT) score was determined in 80 patients; 20 (25%), 17 (21%), 33 (41%) and 10 (13%) patients had scores of 0-1, 2, 3 and 4, respectively.
  • Further research is needed to better risk-stratify this unique lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).
  • METHODS: Patients with solid tumor, lymphoma or leukemia diagnoses without standard treatment options were treated with IV NPI on Days 1, 8 and 15 of 28-day cycles in a 3+3 design dose escalation to a Recommended Phase 2 Dose (RP2D).
  • Enrollment then began in 10 patient lymphoma and CLL RP2D cohorts.
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bonini A, Tieghi A, Gamberi B, Imovilli A, Carbonelli C, Spaggiari L, Gugliotta L: Caspofungin for invasive aspergillosis: A single-centre prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Since 2004 we began a prospective study with the administration of Caspo as first line therapy in 63 consecutive adult neutropenic pts.
  • The diagnoses were: leukemia 44, myeloma 3, lymphoma 16; the disease's phases were: new onset 24, remission 16, relapse 23.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961616.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Henderson TO, Hlubocky F, Diller L, Daugherty C: Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol; 2009 May 20;27(15_suppl):6561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 84% of respondents report eventually referring CCS to a LTFU program (40%), to a primary care physician (23%) or to an adult oncologist (12%).
  • In a clinical vignette of 29 year old women exposed to mantle radiation and anthracyclines (150 mg/m2) for Hodgkin's lymphoma at 16 years of age: 30% of respondents did not appropriately recommend yearly breast cancer surveillance (based on Children's Oncology Group LTFU guidelines); 41% of respondents did not appropriately recommend cardiac surveillance; and 15% of respondents did not appropriately recommend yearly thyroid screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963799.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bleyer A, Friedman S, Finnegan S, Montello M, Budd T, Anderson B, Trimble EL: Association of adolescent and young adult cancer treatment trial activity with a national mortality reduction benefit in the United States. J Clin Oncol; 2009 May 20;27(15_suppl):6605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of adolescent and young adult cancer treatment trial activity with a national mortality reduction benefit in the United States.
  • : 6605 Background: Adolescent and young adult (AYA) cancer patients in the U.S. have had less mortality and survival improvement than have children or older adults with cancer.
  • Among 15-29 year-olds nearly all of the increased accrual occurred in patients with leukemia or lymphoma, in whom the ratio of the national death rate to SEER incidence fell below the projected linear regression for this ratio in each year during 2002-2005.
  • CONCLUSIONS: In the U.S., COG is now contributing more AYA patients to NCTT than any adult cooperative group, suggesting that the adult-treating groups and cancer centers have increased capability to increase AYA accrual and should complement the pediatric effort.
  • These favorable trends should encourage implementation of the clinical trial recommendations of the NCI Program Review Group in AYA Oncology ( http://planning.cancer.gov/disease/AYAO_PRG_Report_2006_FINAL.pdf ) that are being implemented in part by the LIVESTRONG Young Adult Alliance (Closing the Gap: A Strategic Plan).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rao SR, Hassett M, Schwartz JH, Maloney B, Jacobson JO: Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol; 2009 May 20;27(15_suppl):6571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a prospective cohort study of adult cancer patients (excluding acute leukemia and stem cell transplant patients) admitted to a community hospital January 2003-December 2006.
  • The most common cancers were colorectal (18.5%), lung (18.1%), lymphoma (16.3%), and breast (13.7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Gercovich FG, Gil Deza E, Martin Reina G, Garcia Gerardi C, Abal M, Santillan D, Tognelli F, Calarame J, Rivarola E, Morgenfeld E: 300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real? J Clin Oncol; 2009 May 20;27(15_suppl):e17535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17535 Background: Juvenile Cancer (JC) involves patients between 18 and 29 years old (adult pt less than 30 yo) and can be or not associated to AIDS.
  • DIAGNOSIS: Expected tumors 269 pt (80%) (testicular tumors = 89 pt; lymphoma = 75 pt; sarcoma = 35 pt; melanoma = 17 pt; others = 53), Unexpected tumors 67 pt (20%) (gastrointestinal = 23 pt; breast cancer = 17 pt; ovarian = 13 pt; head and neck = 7 pt; others = 7 pt).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Tan H, Tomic K, Daniel G, Hurley D, Barron R: Evaluating risk of hospitalization with G-CSF use in real-world oncology practice. J Clin Oncol; 2009 May 20;27(15_suppl):6626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective analysis of administrative claims from U.S. commercial health plans identified adult patients with non-Hodgkin's lymphoma, breast, or lung cancer, treated with chemotherapy between July 2004 and January 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961802.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Meany HJ, Gidvani VK, Minniti CP: Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer; 2007 Apr;48(4):399-402
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma.
  • Numerous studies report that PET scan offers increased sensitivity, specificity and predictive values as compared to computed tomography (CT) in adult lymphoma patients.
  • PROCEDURE: Twenty-three consecutive pediatric Hodgkin lymphoma (HL) patients were evaluated with PET scan either at diagnosis or during treatment, then at therapy completion and in follow-up.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514616.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ: Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol; 2009 May 20;27(15_suppl):8547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.
  • : 8547 Background: Increased late mortality and morbidity have been observed among adult survivors of Hodgkin lymphoma (HL) treated in childhood, but are less well characterized for patients treated in adulthood.
  • METHODS: We investigated the late mortality and morbidity of adult patients treated at our center from 1975 to 2000.
  • These findings underscore the importance of efforts directed at prevention of and early intervention for late morbidity in adult survivors of HL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960964.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Müller J, Molnár Z, Illés A, Csóka M, Jakab Z, Deák B, Schneider T, Várady E, Rosta A, Simon Z, Keresztes K, Gergely L, Kovács G: [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?]. Orv Hetil; 2008 Nov 23;149(47):2221-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?].
  • [Transliterated title] Hodgkin-lymphoma adolescens korban. Hol érdemes kezelni: felnôtt- vagy gyermekintézményben?
  • Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards.
  • AIM: The aim of our work was to compare the treatment modalities and the survival rates in adolescents with HL treated in adult (A) or pediatric (P) institutes.
  • METHODS: From January 1990 to December 2004, 138 patients (14-21 years) with HL were treated in two adult institutes (A) and 107 in the 10 centres of the Hungarian Pediatric Oncology Network (P).
  • Event-free survival was higher in pediatric than in adult institutes.
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Hungary / epidemiology. Male. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Retrospective Studies. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004744.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; OPPA protocol
  •  go-up   go-down


25. Kollár B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M: [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions]. Orv Hetil; 2009 Aug 30;150(35):1649-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
  • [Transliterated title] Pimer gastrointestinalis non-Hodgkin-lymphoma két magyarországi régió beteganyaga alapján.
  • Over the past few decades, the occurrence of adult onset non-Hodgkin's lymphoma has significantly increased.
  • The treatment strategy for non-Hodgkin's lymphoma has changed over the past decade: chemo-immunotherapy has largely taken over surgical intervention, the dominant treatment option of the past.
  • METHODS: The authors present their experience with 48 patients with non-Hodgkin's lymphoma, affecting the gastrointestinal tract, treated in Kaposvár, in the Kaposi Mór Teaching Hospital and in Gyula, in the Pándy Kálmán County Hospital.
  • RESULTS: The most frequently involved GI organ was the stomach ( n = 26), with the dominant histological type of diffuse large B-cell lymphoma.
  • Patients with upper gastrointestinal tract involvement carried the best prognosis (IPI: 2.0); at the same time, patients with stomach lymphoma achieved the highest rate of remission (73%).
  • IPI index represents the most recognised indicator for assessing the prognosis of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Hungary / epidemiology. Incidence. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Risk Assessment. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692309.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


26. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Jóna A, Illés A: [Changing patterns in the clinical, pathological features of Hodgkin lymphoma]. Orv Hetil; 2010 Dec 5;151(49):2011-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing patterns in the clinical, pathological features of Hodgkin lymphoma].
  • [Transliterated title] Változnak-e a Hodgkin-lymphoma klinikopatológiai jellemzői?
  • Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as well.
  • PATIENTS AND METHODS: The Authors analyzed 439 Hodgkin lymphoma patients' clinicopathological and treatment data.
  • RESULTS: The first period contained 117 patients, the second 147 and third 115 Hodgkin lymphoma patients.
  • CONCLUSIONS: Changes can be explained by the altered nature of Hodgkin lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods.
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Hungary / epidemiology. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Distribution. Socioeconomic Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21106481.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


27. Carrié E, Buzyn A, Fraitag S, Hermine O, Bodemer C: [Transformed juvenile-onset mycosis fungoides: treatment by bone marrow transplantation with graft-versus-lymphoma effect]. Ann Dermatol Venereol; 2007 May;134(5 Pt 1):471-6
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transformed juvenile-onset mycosis fungoides: treatment by bone marrow transplantation with graft-versus-lymphoma effect].
  • [Transliterated title] Mycosis fongoïde transformé chez un enfant: traitement par transplantation médullaire allogénique avec effet "graft-versus-lymphoma"
  • BACKGROUND: Mycosis fungoides is the most frequent cutaneous T-cell lymphoma but has been rarely reported in children and teenagers.
  • Although transformation into large-cell T-cell lymphoma has been described in 10% of adult cases, it is seen very rarely in children.
  • Following the recurrence of skin lesions 2 years later, donor lymphocytes were administered in addition to treatment with interferon alpha, aiming at stimulating a graft-versus-lymphoma reaction.
  • Juvenile mycosis fungoides represents 2.5 to 5% of cases of mycosis fungoides and transformation to large cell lymphoma is exceptional.
  • Our case illustrates the aggressive pattern observed in some teenage patients as well as the efficacy of bone marrow allograft, most likely thanks chiefly to its graft-versus-lymphoma effect.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Tumor Effect. Lymphoma, T-Cell / surgery. Mycosis Fungoides / surgery

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507848.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


28. Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K, Kyushu Hematology Organization for Treatment Study Group (K-HOT): THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol; 2010 May;84(5):391-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
  • OBJECTIVE: The efficacy of pirarubicin (THP)-COP was previously compared with cyclophophamide + doxorubicin + vincristine + prednisolone (CHOP) in elderly patients with lymphoma.
  • The subset analysis showed that T-cell lymphoma had a significantly better response with THP-COP, whereas no such difference was observed in B-cell lymphoma.
  • The aim of this study is to confirm the efficacy of THP-COP in the treatment of T-cell lymphoma.
  • METHODS: We underwent a multicenter phase II study of THP-COP as a first-line treatment for T-cell lymphoma.
  • Seventeen patients had peripheral T-cell lymphoma (PTCL), including nine of PTCL not otherwise specified (PTCL-NOS) and eight of angioimmunoblastic T-cell lymphoma (AITL).
  • Thirty-six patients had adult T-cell leukemia/lymphoma (ATLL), including 20 of acute type and 16 of lymphoma type.
  • CONCLUSION: The efficacy of THP-COP is equivalent to that of CHOP for the first-line therapy in T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Female. Humans. Male. Middle Aged. Prednisolone / adverse effects. Prednisolone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20059527.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


29. Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV: Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol; 2008 Apr;83(4):279-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients.
  • Using allele-specific hybridization on the biochip 76 T-cell non-Hodgkin's lymphoma (NHL) patients, 83 B-cell chronic lymphocytic leukemia (B-CLL) patients, and 177 healthy donors were tested.
  • [MeSH-major] Biotransformation / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, T-Cell / genetics. Oligonucleotide Array Sequence Analysis. Xenobiotics / pharmacokinetics
  • [MeSH-minor] Adult. Alleles. Arylamine N-Acetyltransferase / genetics. Carcinogens, Environmental / pharmacokinetics. Cytochrome P-450 Enzyme System / genetics. Female. Ferredoxin-NADP Reductase / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Humans. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Nucleic Acid Hybridization. Risk Factors. Russia / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18061941.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Xenobiotics; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


30. Bociek RG: Adult Burkitt's lymphoma. Clin Lymphoma; 2005 Jun;6(1):11-20
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt's lymphoma.
  • Burkitt's lymphoma is a mature B-cell lymphoma that is characterized by a rapid proliferative rate and propensity for extranodal sites of involvement such as the gastrointestinal tract and central nervous system.
  • This subtype of non-Hodgkin's lymphoma is associated with unique cytogenetic translocations involving the c-MYC oncogene on chromosome 8, which appears to be involved in the pathogenesis of this disease.
  • Although current literature is limited by a lack of randomized trials, Burkitt's lymphoma appears to be curable in a high proportion of cases if treated with aggressive multiagent chemotherapy regimens.
  • Patients with HIV-associated Burkitt's lymphoma appear to have a better prognosis today, which is likely a result of more effective antiretroviral therapy and the ability to treat selected patients with more aggressive chemotherapeutic regimens than before.
  • This article will review the epidemiologic, biologic, diagnostic, and therapeutic aspects of Burkitt's lymphoma in adults.
  • [MeSH-major] Burkitt Lymphoma
  • [MeSH-minor] Adult. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989701.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


31. Matutes E: Adult T-cell leukaemia/lymphoma. J Clin Pathol; 2007 Dec;60(12):1373-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukaemia/lymphoma.
  • Adult T-cell leukaemia/lymphoma (ATLL) is a mature T-cell neoplasm of post-thymic lymphocytes aetiologically linked to the human T-cell lymphotropic virus, HTLV-I, and with a distinct geographical distribution.
  • According to the disease manifestations, various forms which differ in clinical course and prognosis have been recognised: acute, chronic, smouldering and lymphoma.
  • The latter comprise: lymphocyte morphology, immunophenotype, histology of the tissues affected in the pure lymphoma forms and serology or DNA analysis for HTLV-I.
  • The clinical course is aggressive with a median survival of less than 12 months in the acute and lymphoma forms.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunophenotyping. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Oct 1;56(7):1688-90 [2992744.001]
  • [Cites] Int J Cancer. 1985 Jan 15;35(1):65-72 [2578441.001]
  • [Cites] Lancet. 1987 Jul 11;2(8550):94-5 [2885585.001]
  • [Cites] Blood. 1987 Nov;70(5):1554-64 [2889485.001]
  • [Cites] Blood. 1988 Apr;71(4):1027-32 [2895676.001]
  • [Cites] Lancet. 1990 Oct 20;336(8721):987-90 [1977015.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):76-7 [1670727.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1622-8 [2001551.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1834-7 [7967729.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Leukemia. 1995 Apr;9(4):594-7 [7723390.001]
  • [Cites] Leukemia. 1995 Apr;9(4):598-604 [7723391.001]
  • [Cites] Br J Haematol. 1995 Mar;89(3):615-9 [7734362.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Leuk Lymphoma. 1995 May;17(5-6):459-64 [7549838.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):703-11 [9674744.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):511-5 [16098064.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):637-40 [10609805.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1392-6 [18042695.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Am J Hematol. 2004 Jun;76(2):187-9 [15164389.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • (PMID = 18042693.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 42
  • [Other-IDs] NLM/ PMC2095573
  •  go-up   go-down


32. Jacobsen E, LaCasce A: Update on the therapy of highly aggressive non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2006 Jul;6(7):699-708
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the therapy of highly aggressive non-Hodgkin's lymphoma.
  • This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma. Lymphoma, Non-Hodgkin. Lymphoma, T-Cell. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Child. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805709.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


33. Salaverria I, Zettl A, Beà S, Hartmann EM, Dave SS, Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC, Weisenburger DD, Lopez-Guillermo A, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E, Rosenwald A, Leukemia and Lymphoma Molecular Profiling Project (LLMPP): Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica; 2008 Sep;93(9):1327-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
  • BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma characterized by typical morphological, immunophenotypic and molecular features.
  • Gene expression profiling provided a molecular signature of Burkitt's lymphoma, but also demonstrated that a subset of aggressive B-cell lymphomas not fulfilling the current World Health Organization criteria for the diagnosis of Burkitt's lymphoma nonetheless show a molecular signature of Burkitt's lymphoma ('discrepant Burkitt's lymphoma').
  • Given the different treatment of Burkitt's lymphoma and diffuse large B-cell lymphomas we investigated molecular differences within gene expression-defined Burkitt's lymphoma.
  • DESIGN AND METHODS: We studied tumors from 51 Burkitt's lymphoma patients, comprising 26 with classic Burkitt's lymphoma, 17 with atypical Burkitt's lymphoma and 8 with 'discrepant Burkitt's lymphoma', by comparative genomic hybridization and gene expression profiling.
  • RESULTS: Classic and atypical Burkitt's lymphoma (excluding 'discrepant Burkitt's lymphoma'), in adult and pediatric cases do not differ in underlying genomic imbalances or gene expression suggesting that these subgroups are molecularly homogeneous.
  • 'Discrepant Burkitt's lymphoma', however, differ dramatically in the absolute number of alterations from classic/atypical Burkitt's lymphoma and from diffuse large B-cell lymphoma.
  • Moreover, this category includes lymphomas that carry both the t(14;18) and t(8;14) translocations and are clinically characterized by presentation in adult patients and an aggressive course.
  • CONCLUSIONS: Pediatric and adult Burkitt's lymphoma are molecularly homogeneous, whereas 'discrepant Burkitt's lymphoma' differ in underlying genetic and clinical features from typical/atypical Burkitt's lymphoma.
  • 'Discrepant Burkitt's lymphoma' may therefore form a distinct genetic subgroup of aggressive B-cell lymphomas, which show poor response to multi-agent chemotherapy.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human / genetics. Comparative Genomic Hybridization. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698080.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / UO1-CA84967
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


34. Freed J, Kelly KM: Current approaches to the management of pediatric Hodgkin lymphoma. Paediatr Drugs; 2010 Apr 1;12(2):85-98
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current approaches to the management of pediatric Hodgkin lymphoma.
  • Hodgkin lymphoma is one of the few cancers that affect both adults and children.
  • Cure rates for Hodgkin lymphoma remain among the best for pediatric cancers.
  • In addition, response assessment by fluorine-18-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) may be particularly important in pediatric Hodgkin lymphoma; it may allow modification of treatment to maximize treatment efficacy and minimize late effects of chemotherapy and radiation therapy.
  • Despite the improvements in treatment for all stages of Hodgkin lymphoma, there is still a subgroup of patients who do not enter remission with initial therapy or relapse after initial response to therapy.
  • While there is no standard of care in terms of salvage chemotherapy, high-dose chemotherapy with autologous stem cell transplant (ASCT) rescue has become the standard of care for the majority of children with relapsed Hodgkin lymphoma.
  • The use of allogeneic transplantation is controversial in relapsed or refractory Hodgkin lymphoma; because of the high transplant-related mortality, allogeneic transplant has not been associated with improved overall survival over ASCT.
  • As more has been learned about the biologic mechanisms involved in Hodgkin lymphoma, biologically-based therapies are being investigated for use in this disease, both at initial diagnosis and relapse.
  • Both immunotherapy and small molecules are being studied as possible therapeutic agents in Hodgkin lymphoma.
  • Unfortunately, the vast majority of investigations of novel agents have occurred exclusively in adult patients.
  • However, since pediatric Hodgkin lymphoma and adult Hodgkin lymphoma are similar, these results may potentially be extrapolated to pediatric Hodgkin lymphoma.
  • [MeSH-minor] Adult. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Neoplasm Staging. Remission Induction / methods. Risk Factors. Salvage Therapy / methods. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218745.001).
  • [ISSN] 1179-2019
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 73
  •  go-up   go-down


35. Perkins AS, Friedberg JW: Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program; 2008;:341-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults.
  • This review will begin with a detail of the revision of the WHO classification, and pathological definitions of Burkitt lymphoma.
  • Over the past several years, molecular understanding of Burkitt lymphoma has improved significantly.
  • Using gene expression profiling, a genomic "signature" of Burkitt lymphoma may be identified, that has fidelity beyond c-myc expression, and the presence of the classical t(8;14).
  • Then, evaluation and therapy of the adult patient with Burkitt lymphoma will be reviewed.
  • Relatively few data exist on optimal therapy of the adult patient with Burkitt lymphoma.
  • The outcome of adult patients with Burkitt lymphoma, particularly those over 40 years of age, is inferior to the outcome of younger patients, but may be improving over the past few years.
  • Results from an international collaborative effort, which are helpful in evaluating results of Burkitt lymphoma therapy in adults, will be presented.
  • HIV-associated Burkitt lymphoma, and elderly patients with Burkitt lymphoma, comprise special clinical situations that will be also covered in this review.

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074108.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


36. Bacon CM, Ye H, Diss TC, McNamara C, Kueck B, Hasserjian RP, Rohatiner AZ, Ferry J, Du MQ, Dogan A: Primary follicular lymphoma of the testis and epididymis in adults. Am J Surg Pathol; 2007 Jul;31(7):1050-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular lymphoma of the testis and epididymis in adults.
  • Primary follicular lymphoma of the adult testis has not been well characterized.
  • Here, we describe 5 cases of primary follicular lymphoma of the testis and epididymis in adults.
  • These features are different from those of most adult nodal follicular lymphomas but are very similar to those of the pediatric primary testicular follicular lymphomas.
  • Together, the pediatric and adult cases represent a discrete clinicopathologic entity of t(14;18)(q32;q21)/IGH-BCL2-negative primary follicular lymphoma of the testis and epididymis, which typically present as clinically indolent localized disease in young males and should be distinguished from the diffuse large B-cell lymphoma more frequently seen in the testes of older adults.
  • [MeSH-major] Epididymis / pathology. Lymphoma, Follicular / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592272.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Peral-Cagigal B, Galdeano-Arenas M, Crespo-Pinilla JI, García-Cantera JM, Sánchez-Cuéllar LA, Verrier-Hernández A: Centrofacial angiocentric lymphoma. Med Oral Patol Oral Cir Bucal; 2005 Jan-Feb;10(1):92-4; 90-2
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centrofacial angiocentric lymphoma.
  • The centrofacial angiocentric lymphoma is a rare lymphoid neoplasm, with an often-difficult diagnosis due to the non-specific clinical picture.
  • This lymphoma is an aggressive Non-Hodgkin's (NHL) type, which is normally found in the upper respiratory tract (predominantly in the nasal cavity), and has an ominous prognosis, as the average survival rate is between 12 and 18 months (1).
  • After performing a number of diagnostic tests, it was found histologically that the patient had an extranodal T-cell lymphoma of the nasal type (also known as T-cell angiocentric lymphoma).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15627913.001).
  • [ISSN] 1698-4447
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


38. Rodríguez-Vázquez M, García-Arpa M, Martín F, Calle C, Marchán E, Romero G, Cortina P: [Panniculitic T-cell lymphoma]. Actas Dermosifiliogr; 2005 Mar;96(2):98-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Panniculitic T-cell lymphoma].
  • Panniculitic T-cell lymphoma is a rare, aggressive variant of cutaneous T-cell lymphoma, with fewer than 100 cases described.
  • After two skin biopsies, the patient was diagnosed with panniculitic cutaneous T-cell lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Cellulitis / pathology. Diagnostic Errors. Humans. Male. Panniculitis / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476344.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 28
  •  go-up   go-down


39. Tabata R, Tabata C, Namiuchi S, Terada M, Yasumizu R, Okamoto T, Nagai T: Adult T-cell lymphoma mimicking Henoch-Schönlein purpura. Mod Rheumatol; 2007;17(1):57-62
Genetic Alliance. consumer health - Henoch-Schonlein purpura.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell lymphoma mimicking Henoch-Schönlein purpura.
  • We report a male patient with adult T-cell lymphoma, who was initially diagnosed clinically as having Henoch-Schönlein purpura (HSP) with abdominal pain and specific purpura.
  • Adult T-cell lymphoma-like cells were minimal and abdominal lymph nodes were transiently swollen, and the symptoms were improved by supportive management.
  • Later he developed lymphoma and was treated with chemotherapy.
  • This rare case suggests the importance of skin biopsies to seek the underlying pathology in adult HSP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278024.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Mounier N, Fermé C: [Particularities of Hodgkin's lymphoma]. Rev Prat; 2010 Jan 20;60(1):75-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Particularities of Hodgkin's lymphoma].
  • A risk-adapted strategy for adult patients with Hodgkin's lymphoma is based on risk factors at diagnosis.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222316.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


41. Foltz LM, Song KW, Connors JM: Hodgkin's lymphoma in adolescents. J Clin Oncol; 2006 Jun 1;24(16):2520-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in adolescents.
  • PURPOSE: To compare the clinical presentation, response to treatment, and long-term outcome of Hodgkin's lymphoma (HL) presenting in adolescents and young adults.
  • All patients were treated using adult protocols.
  • The use of adult treatment protocols is a safe and effective strategy for treating adolescents with HL.
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. British Columbia. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Incidence. Male. Mechlorethamine / administration & dosage. Medical Record Linkage. Neoplasm Staging. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prospective Studies. Radiotherapy, Adjuvant. Registries. Risk Assessment. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


42. Kelemen K, Braziel RM, Gatter K, Bakke TC, Olson S, Fan G: Immunophenotypic variations of Burkitt lymphoma. Am J Clin Pathol; 2010 Jul;134(1):127-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic variations of Burkitt lymphoma.
  • Burkitt lymphoma (BL) exhibits a characteristic immunophenotype that is positive for pan-B-cell antigens and CD10 and expresses clonal surface immunoglobulins (SIgs).
  • [MeSH-major] Burkitt Lymphoma / immunology. Immunophenotyping. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Chromosome Aberrations. Female. Flow Cytometry. Humans. Immunoglobulin kappa-Chains / genetics. In Situ Hybridization, Fluorescence. Male. Middle Aged. Remission Induction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551277.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


43. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


44. Olivo RA, Martins FF, Soares S, Moraes-Souza H: Adult T-cell leukemia/lymphoma: report of two cases. Rev Soc Bras Med Trop; 2008 May-Jun;41(3):288-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma: report of two cases.
  • Adult T-cell leukemia/lymphoma is a lymphoproliferative disorder of mature T lymphocytes associated with infection with human T-cell lymphotrophic virus type I (HTLV-I).
  • Adult T-cell leukemia/lymphoma is characterized by clinical and laboratory polymorphism that allows it to be classified into four distinct subgroups: smoldering, chronic, acute and lymphomatous types.
  • We present here two cases of adult T-cell leukemia/lymphoma, respectively in the acute and lymphomatous forms of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719810.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


45. Hokama A, Tomoyose T, Yamamoto Y, Watanabe T, Hirata T, Kinjo F, Kato S, Ohshima K, Uezato H, Takasu N, Fujita J: Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis. World J Gastroenterol; 2008 Nov 14;14(42):6584-8
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis.
  • Multiple lymphomatous polyposis (MLP) is an unusual form of non-Hodgkin's lymphoma characterized by polyps throughout the gastrointestinal tract.
  • It has been reported that most MLP are observed in cases with mantle cell lymphoma of B-cell type.
  • We herein present a case of a 66-year-old man with adult T-cell leukemia/lymphoma (ATLL).
  • [MeSH-major] Colonic Polyps / etiology. Intestinal Polyposis / etiology. Leukemia-Lymphoma, Adult T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1993 Oct;11(3-4):281-6 [8260899.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1768-73 [18350608.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):261 [14745401.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):805-8 [14997894.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):788-92 [15338374.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):824-8 [3257406.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):708-16 [8431850.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3042-50 [7954267.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):396-402 [8697382.001]
  • [Cites] Endoscopy. 1995 Nov;27(9):700-3 [8903987.001]
  • [Cites] J Gastroenterol. 1997 Aug;32(4):553-7 [9250907.001]
  • [Cites] J Clin Immunol. 1999 May;19(3):186-93 [10404404.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):983-4 [15605016.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Trop Med Hyg. 2006 Feb;74(2):246-9 [16474078.001]
  • [Cites] Gut. 2006 Nov;55(11):1574, 1591 [17047108.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):266-81 [17376384.001]
  • [Cites] Gastrointest Endosc. 2007 Apr;65(4):712-3 [17383471.001]
  • [Cites] Cancer Sci. 2007 Jun;98(6):772-8 [17388788.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):241-6 [11500618.001]
  • (PMID = 19030219.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 24
  • [Other-IDs] NLM/ PMC2773353
  •  go-up   go-down


46. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M: Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol; 2007 Apr;85(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
  • We analyzed NOTCH1 gene mutation in 53 adults with mature T-cell leukemia/lymphoma: 21 patients with adult T-cell leukemia (ATL), 25 with T-cell non-Hodgkin's lymphoma (T-NHL), and 7 with T-cell prolymphocytic leukemia.
  • We detected a nonsense mutation, C7249T (resulting in Q2417X, where X is a termination codon) in the PEST domain of NOTCH1 in an ATL patient and detected a 3-bp deletion (positions 7234-7236) that resulted in deletion of a proline codon at codon 2412 in the PEST domain of NOTCH1 in a patient with a T-NHL, peripheral T-cell lymphoma-unspecified (PTCL-u).
  • Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
  • [MeSH-major] Codon, Nonsense. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. Humans

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483057.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


47. Tobinai K: Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park); 2009 Dec;23(14):1250-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of adult T-cell leukemia/lymphoma.
  • When oncologists diagnose patients suspected of lymphoid malignancy, it is important to consider the possibility of adult T-cell leukemia/lymphoma (ATL) with a routine check for serum human T-cell lymphotropic virus type 1 (HTLV-1) antibody.
  • For patients with the acute or lymphoma type requiring therapy, enrollment in a clinical trial is recommended.
  • When there is no active trial or the patient is ineligible for a trial, we recommend intensive chemotherapy used for aggressive non-Hodgkin lymphoma such as the LSG15 regimen (VCAP-AMP-VECP) based on a recent phase III study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Deltaretrovirus Antibodies / blood. Female. Hematopoietic Stem Cell Transplantation. Humans. Kaplan-Meier Estimate. Male. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Dec;23(14):1267, 1270 [20120839.001]
  • [CommentIn] Oncology (Williston Park). 2009 Dec;23(14):1256, 1261, 1266 [20120838.001]
  • (PMID = 20120837.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Deltaretrovirus Antibodies
  •  go-up   go-down


48. Wada T, Yoshinaga E, Oiso N, Kawara S, Kawada A, Kozuka T: Adult T-cell leukemia-lymphoma associated with follicular mucinosis. J Dermatol; 2009 Dec;36(12):638-42
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia-lymphoma associated with follicular mucinosis.
  • Follicular mucinosis (alopecia mucinosa) is often associated with malignancies including mycosis fungoides and Sézary syndrome, but not adult T-cell leukemia-lymphoma (ATLL).
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Mucinosis, Follicular / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958447.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


49. Mahieux R, Gessain A: Adult T-cell leukemia/lymphoma and HTLV-1. Curr Hematol Malig Rep; 2007 Oct;2(4):257-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma and HTLV-1.
  • Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago.
  • HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).
  • ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type.
  • Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations.
  • [MeSH-major] Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. CD4-Positive T-Lymphocytes / virology. Clinical Trials as Topic. Drug Resistance, Neoplasm. Endemic Diseases. Female. Gene Products, tax / physiology. Genes, pX. Humans. Immunoglobulin G / therapeutic use. Immunophenotyping. Immunotherapy. Infant, Newborn. Infectious Disease Transmission, Vertical. Interferon-alpha / therapeutic use. Male. Oxides / therapeutic use. Paraparesis, Tropical Spastic / epidemiology. Paraparesis, Tropical Spastic / virology. Pregnancy. Pregnancy Complications, Infectious. Zidovudine / therapeutic use

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425378.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Gene Products, tax; 0 / Immunoglobulin G; 0 / Interferon-alpha; 0 / Oxides; 0 / tax protein, Human T-lymphotrophic virus 1; 3A189DH42V / alemtuzumab; 4B9XT59T7S / Zidovudine; CUJ2MVI71Y / daclizumab; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 63
  •  go-up   go-down


50. Pezeshkpoor F, Yazdanpanah MJ, Shirdel A: Specific cutaneous manifestations in adult T-cell leukemia/lymphoma. Int J Dermatol; 2008 Apr;47(4):359-62
Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific cutaneous manifestations in adult T-cell leukemia/lymphoma.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy which may occur in individuals infected with human T-cell lymphotropic virus type-I (HTLV-I).
  • As specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied these manifestations in ATLL patients admitted to the Hematology and Dermatology Departments of Ghaem Hospital, Mashhad, Iran, during 1995-2004.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Skin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Iran. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377598.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP: Primary lymphoma of bone in adult patients. Cancer; 2010 Feb 15;116(4):871-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of bone in adult patients.
  • BACKGROUND: The low incidence of primary lymphoma of bone (PLB) has led to discrepancies in classification as well as difficulty in prognostication.
  • The authors of this report used the Surveillance, Epidemiology, and End Results (SEER) database to analyze a large, population-based cohort of adult patients with this disease.
  • RESULTS: Fifteen hundred adult patients with PLB were analyzed.
  • The 5-year and 10-year survival rates for adult patients were 58% and 45%, respectively.
  • [MeSH-major] Bone Neoplasms / mortality. Lymphoma / classification. Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Male. Middle Aged. Population Surveillance. Prognosis. SEER Program. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043324.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors
  • [MeSH-minor] Adult. Child. Cognition Disorders / etiology. Endocrine System / physiopathology. Follow-Up Studies. Humans. Neoplasms, Radiation-Induced. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


53. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • 10 patients had diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


54. Machijima Y, Ishikawa C, Sawada S, Okudaira T, Uchihara JN, Tanaka Y, Taira N, Mori N: Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol. Retrovirology; 2009;6:7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is a malignancy derived from T cells infected with human T-cell leukemia virus type 1 (HTLV-1), and it is known to be resistant to standard anticancer therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Survival / drug effects. Human T-lymphotropic virus 1 / drug effects. Indoles / pharmacology. Indoles / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. T-Lymphocytes

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):123-9 [10926790.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6351-60 [11101508.001]
  • [Cites] Virology. 2001 Jan 5;279(1):38-46 [11145887.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1094-102 [11314046.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):595-601 [11332715.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2927-36 [11420705.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):165-70 [15044019.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):596-601 [15245597.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5233-41 [15297427.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):985-8 [1127728.001]
  • [Cites] Cancer Res. 1978 May;38(5):1410-3 [416908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Science. 1982 Aug 20;217(4561):737-9 [6980467.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):221-8 [6088403.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):225-31 [2161813.001]
  • [Cites] Cell. 1996 Mar 22;84(6):853-62 [8601309.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):9090-9 [8621559.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):3980-7 [8892631.001]
  • [Cites] Cancer Lett. 1997 Sep 16;118(1):87-94 [9310264.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):211-6 [9653098.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3991-7 [10463597.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3493S-3498S [15570059.001]
  • [Cites] J Nutr Biochem. 2005 Feb;16(2):65-73 [15681163.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):967-74 [15729715.001]
  • [Cites] Blood. 2005 Jul 15;106(2):641-9 [15811958.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1953-60 [16103443.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1842-53 [16087329.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5965-75 [16155603.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1201-15 [16082211.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8521-7 [16322316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):786-90 [16681761.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2747-56 [17121921.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2477-81 [17164373.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Retrovirology. 2007;4:92 [18078517.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2286-94 [18771528.001]
  • [Cites] Jpn J Cancer Res. 2000 Jan;91(1):34-40 [10744042.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] Food Chem Toxicol. 2000 Jan;38(1):15-23 [10685010.001]
  • (PMID = 19146708.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / Indoles; C11E72455F / indole-3-carbinol
  • [Other-IDs] NLM/ PMC2635345
  •  go-up   go-down


55. Goswami T, Siddique S, Cohen P, Cheson BD: The sarcoid-lymphoma syndrome. Clin Lymphoma Myeloma Leuk; 2010 Aug;10(4):241-7
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sarcoid-lymphoma syndrome.
  • Whether a relationship exists between sarcoidosis and lymphoma is controversial.
  • We present 4 patients diagnosed with sarcoidosis either during or after the treatment of lymphoma, review the data surrounding the entity known as "sarcoid-lymphoma syndrome" and discuss the diagnostic pitfalls it can present.
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / pathology. Sarcoidosis / diagnosis. Sarcoidosis / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Positron-Emission Tomography. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709659.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


56. Gooding L: Lymphoma network. Nurs Stand; 2005 Jul 20-26;19(45):22-3
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma network.
  • While some cancers get a great deal of media coverage, lymphoma is something of the poor relation, although there are about 11,000 new cases a year in the UK.
  • Gill Woods has taken on the role of the first clinical nurse specialist in lymphoma to help patients understand their condition.
  • [MeSH-major] Lymphoma / nursing. Specialties, Nursing / organization & administration
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. England. Humans. Middle Aged. Nurse's Role. Nurse-Patient Relations. Patient Care Team / organization & administration. Patient Education as Topic / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050223.001).
  • [ISSN] 0029-6570
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Jarrett RF: Viruses and lymphoma/leukaemia. J Pathol; 2006 Jan;208(2):176-86
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viruses and lymphoma/leukaemia.
  • The human T-cell leukaemia virus type 1 causes adult T-cell leukaemia and the Epstein-Barr virus is associated with Burkitt's lymphoma, lymphomas in immunosuppressed people, and Hodgkin lymphoma.
  • Individuals infected with the human immunodeficiency virus are at greatly increased risk of developing lymphoma but here the mechanism of lymphomagenesis is indirect.
  • Recent data suggest that hepatitis C virus infection is also associated with an increased incidence of lymphoma, whereas data relating to SV40 remain controversial.
  • [MeSH-major] Leukemia / virology. Lymphoma / virology
  • [MeSH-minor] Adult. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. HIV / immunology. Hepacivirus / immunology. Herpesvirus 1, Cercopithecine / immunology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / immunology. Hodgkin Disease / genetics. Hodgkin Disease / immunology. Hodgkin Disease / virology. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / immunology. Humans. Simian virus 40 / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [CommentIn] J Pathol. 2006 Jul;209(3):420-1; author reply 422-4 [16639695.001]
  • (PMID = 16362996.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 105
  •  go-up   go-down


58. Vu H, Vildor E, Reddy S, Phillips J, Meenrajan S, Edwards L, Hosenpud J: An unusual presentation of Burkitt lymphoma. South Med J; 2009 Sep;102(9):961-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of Burkitt lymphoma.
  • We describe a 37-year-old non-smoker who presented with dyspnea and a unilateral effusion secondary to Burkitt lymphoma (BL).
  • Burkitt lymphoma is discussed.
  • [MeSH-major] Burkitt Lymphoma / complications. Burkitt Lymphoma / diagnosis. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Adult. Biopsy. Dyspnea / etiology. Humans. Male. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668043.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Gutiérrez-García L, Medina Ramos N, García Rodríguez R, Barber MA, Arias MD, García JA: Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol; 2009;30(2):231-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian Burkitt's lymphoma.
  • Primary ovarian lymphoma is a rare entity.
  • Histology confirmed Epstein-Barr virus-positive bilateral Burkitt's lymphoma.
  • Endemic Burkitt's lymphoma has a predilection for the female genital tract, manifesting itself clinically as a pelvic mass and less frequently as a menstrual disorder.
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Herpesvirus 4, Human / isolation & purification. Humans

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Malani AK, Gupta C, Weigand RT, Gupta V, Rangineni G: Spinal Burkitt's lymphoma in adults. Clin Lymphoma Myeloma; 2006 Jan;6(4):333-6
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal Burkitt's lymphoma in adults.
  • Adult Burkitt's lymphoma is an uncommon disease.
  • Few cases of spinal involvement in adults with sporadic Burkitt's lymphoma are reported in the literature.
  • Histologic examination revealed a primary Burkitt's lymphoma of the spinal cord.
  • We also present a review of the literature for the etiology and clinical features of other spinal lymphomas and Burkitt's lymphoma involving the spine in adults.
  • [MeSH-major] Burkitt Lymphoma / pathology. Epidural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507212.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Chuang SS, Ichinohasama R, Chu JS, Ohshima K: Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma. Int J Hematol; 2010 May;91(4):687-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of angioimmunoblastic T-cell lymphoma with seropositivity for anti-HTLV antibody from adult T-cell leukemia/lymphoma.
  • Angioimmunoblastic lymphoma (AITL) is a nodal peripheral T-cell lymphoma characterized by a proliferation of arborizing vessels and hyperplastic follicular dendritic cells as well as a polymorphous lymphoid infiltrate including neoplastic cells with clear cytoplasm.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by the retrovirus human T-cell leukemia virus type I (HTLV-I), and the neoplastic cells are usually large and pleomorphic.
  • Here, we presented a case of peripheral T-cell lymphoma with morphological features of AITL in Taiwan, a country non-endemic for HTLV, and the patient was seropositive for anti-HTLV antibody, which raised the possibility of ATLL with AITL-like features.
  • Our investigations indicated that in an HTLV-I non-endemic area, a peripheral T-cell lymphoma with typical morphologic and immunophenotypic features of AITL could be confidently diagnosed as AITL even if the patient was seropositive for anti-HTLV antibody.
  • [MeSH-major] HTLV-I Antibodies / blood. HTLV-I Infections / complications. HTLV-I Infections / immunology. Immunoblastic Lymphadenopathy. Lymphoma, T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198459.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HTLV-I Antibodies
  •  go-up   go-down


62. Wei SZ, Liu TH, Wang DT, Cao JL, Luo YF, Liang ZY: Hepatosplenic gammadelta T-cell lymphoma. World J Gastroenterol; 2005 Jun 28;11(24):3729-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatosplenic gammadelta T-cell lymphoma.
  • AIM: To investigate the clinicopathologic characteristics, immunophenotype and TCR gene rearrangements of hepatosplenic T-cell lymphoma in eight Chinese patients.
  • Histologically, lymphoma cells infiltrated the cords of Billroth and often packed the sinuses.
  • Liver biopsy showed lymphoma cell infiltrations in the sinusoids, and three cases showed involvements of the portal tracts.
  • Immunohistochemically lymphoma cells were positive for CD3, CD43, and CD56 in all cases.
  • CONCLUSION: The clinicopathology of hepatosplenic gammadelta T-cell lymphoma in Chinese patients is similar to what was previously reported except that the splenomegaly is not so massive, and CD8 is positive.
  • [MeSH-major] Liver Neoplasms / immunology. Lymphoma, T-Cell / immunology. Receptors, Antigen, T-Cell, gamma-delta / genetics. Splenic Neoplasms / immunology
  • [MeSH-minor] Adult. Base Sequence. Child. Female. Gene Rearrangement, T-Lymphocyte. Hepatomegaly / pathology. Humans. Immunophenotyping. Male. Middle Aged. Molecular Sequence Data. Splenomegaly / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968729.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC4316025
  •  go-up   go-down


63. Barthwal MS, Deoskar RB, Falleiro JJ, Singh P: Endobronchial non-Hodgkin's lymphoma. Indian J Chest Dis Allied Sci; 2005 Apr-Jun;47(2):117-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial non-Hodgkin's lymphoma.
  • Needle aspiration and endobronchial biopsy from the mass revealed it to be a case of anaplastic large cell lymphoma, a subtype of non-Hodgkin's lymphoma.
  • This report documents the rare presentation of non-Hodgkin's lymphoma as an endobronchial mass.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. India. Male. Risk Assessment. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832956.001).
  • [ISSN] 0377-9343
  • [Journal-full-title] The Indian journal of chest diseases & allied sciences
  • [ISO-abbreviation] Indian J Chest Dis Allied Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


64. Patte C, Ribrag V, Brugières L: [Non Hodgkin's lymphoma in adolescents]. Bull Cancer; 2007 Apr;94(4):339-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in adolescents].
  • In France, adolescents (15-20 years) with non Hodgkin's lymphoma (NHL) are referred either to paediatric or to adult onco-haematological departments.
  • Further studies specific to the adolescents are needed to better know the biology of their lymphoma and to determine the best therapeutic approach.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Child. Clinical Protocols. France / epidemiology. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Medical Oncology / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449436.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 72
  •  go-up   go-down


65. Bakrac M, Bonaci-Nikolić B, Colović N, Simić-Ogrizović S, Krstić M, Colović M: [Enteropathy associated T-cell lymphoma]. Srp Arh Celok Lek; 2007 Jan-Feb;135(1-2):80-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Enteropathy associated T-cell lymphoma].
  • Enteropathy associated T-cell lymphoma (EATCL) is a high grade, pleomorphic peripheral T-cell lymphoma with usually cytotoxic phenotype.
  • Diagnosis of lymphoma was confirmed after the resection of the jejunum (small intestine obstruction).
  • The overall survival of patients was 7 months.The possibility of lymphoma rising in patients with clinical progression of GSE despite gluten free diet must be kept in mind.
  • [MeSH-major] Celiac Disease / complications. Intestinal Neoplasms / complications. Lymphoma, T-Cell, Peripheral / complications
  • [MeSH-minor] Adult. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503573.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


66. Cobzeanu MD, Costinescu V, Rusu CD, Mihailovici S, Grigoras M, Miron L, Paduraru D, Arama A: Laryngotracheal non-Hodgkin's lymphoma. Chirurgia (Bucur); 2010 Jan-Feb;105(1):131-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngotracheal non-Hodgkin's lymphoma.
  • The authors present an unexpected case of nonHodgkin Lymphoma localized in the subglottic larynx and upper cervical trachea.
  • The histopathologic exam of the surgical specimen showed malignant nonHodgkin lymphoma and the immunohistochemical profiles were evaluated in order to establish the therapeutic strategy including chemotherapy in the Department of Oncology.
  • CONCLUSIONS: Invasion of the subglottic larynx and trachea by lymphoma is an uncommon problem which can cause severe airway obstruction and requires multidisciplinary approach (ENT, pneumology, oncology/hematology).
  • [MeSH-major] Laryngeal Neoplasms / pathology. Lymphoma, B-Cell / pathology. Tracheal Neoplasms / pathology
  • [MeSH-minor] Adult. Airway Obstruction / etiology. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Male. Radiotherapy, Adjuvant. Tracheotomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405695.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


67. Rosenberg B: Peripheral T-cell lymphoma. Dermatol Online J; 2005;11(4):5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma.
  • A diagnosis of peripheral T-cell lymphoma was made, and the patient is undergoing chemotherapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403377.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Sweetenham JW: Lymphoblastic lymphoma in adults. Curr Hematol Malig Rep; 2006 Dec;1(4):241-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma in adults.
  • Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Lymphocytes / pathology. Child. Combined Modality Therapy. Gene Expression Regulation, Neoplastic. Gene Rearrangement. Hematopoietic Stem Cell Transplantation. Humans. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Remission Induction. Salvage Therapy. T-Lymphocytes / pathology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425319.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


69. Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ: Radiofrequency ablation of lymphoma. Blood; 2006 Feb 15;107(4):1624-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of lymphoma.
  • Percutaneous minimally invasive radiofrequency (RF) ablation has not been described for lymphoma.
  • This image-guided modality is presented in 3 different settings for the treatment of refractory lymphoma.
  • The second patient received RF ablation for successful palliation of progressive follicular lymphoma adjacent to the bladder wall following chemotherapy and maximum radiation.
  • The third patient received RF ablation for prevention of airway obstruction from progressive diffuse large B-cell lymphoma of the right neck following chemotherapy and maximum radiation.
  • RF ablation may be clinically beneficial and should be considered for the treatment of local lymphoma that is refractory or not amenable to standard approaches.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Radio Waves / therapeutic use
  • [MeSH-minor] Adult. Humans. Kidney Transplantation. Male. Middle Aged. Postoperative Complications. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hyperthermia. 2004 Nov;20(7):781-802 [15675672.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):41-52 [15777889.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):51-7 [15972398.001]
  • [Cites] Tech Vasc Interv Radiol. 2002 Sep;5(3):156-63 [12524646.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):129-47 [11369525.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):41-7 [11842388.001]
  • [Cites] J Chemother. 2004 Nov;16 Suppl 5:86-9 [15675488.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1110-4 [12163638.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9 [12652466.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6496-500 [14559842.001]
  • [Cites] Radiology. 2004 Jan;230(1):169-74 [14645878.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4024-9 [15173017.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2685-93 [11929754.001]
  • (PMID = 16254135.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CL999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1895403
  •  go-up   go-down


70. Herbertson R, Hancock BW: Hodgkin Lymphoma in adolescents. Cancer Treat Rev; 2005 Aug;31(5):339-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin Lymphoma in adolescents.
  • With the development of an integrated treatment approach, the cure rate and survival of patients with Hodgkin Lymphoma (HL) is now high.
  • Future treatment strategies may direct the treatment of adolescents with HL away from the current "adult" regimens, and closer to that currently received by children, but prospective randomised trials are required.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951118.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


71. Dungerwalla M, Osuji N, Waldman AD, Al Jehani F, Mehta A, Tailor R, Wotherspoon A, Cogill G, Matutes E: Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia. Br J Haematol; 2005 Aug;130(4):511-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated central nervous system involvement in adult T-cell lymphoma/leukaemia.
  • Central nervous system (CNS) presentation of adult T-cell lymphoma/leukaemia is rare, and almost invariably associated with systemic disease.
  • We report an unusual manifestation of adult T-cell lymphoma/leukaemia, with isolated CNS involvement and unusual imaging findings.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Disease Progression. Frontal Lobe / surgery. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Palliative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Nov;131(4):557. Taylor, R [corrected to Tailor, R]
  • (PMID = 16098064.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  • [Number-of-references] 22
  •  go-up   go-down


72. Muñoz Martín AJ, Pérez Fernández R, Viñuela Beneítez MC, Martínez Marín V, Marquéz-Rodas I, Sabin Domínguez P, García Alfonso P: Primary ovarian Burkitt lymphoma. Clin Transl Oncol; 2008 Oct;10(10):673-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian Burkitt lymphoma.
  • Primary ovarian Burkitt lymphoma (BL) is a rare neoplasm in adults.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Female. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940750.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


73. Sakamoto FH, Colleoni GW, Teixeira SP, Yamamoto M, Michalany NS, Almeida FA, Chiba AK, Petri V, Fernandes MA, Pombo-de-Oliveira MS: Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma. Int J Dermatol; 2006 Apr;45(4):447-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a malignant proliferation of mature helper T lymphocytes,(1) and is caused by human T-lymphotropic virus type I (HTLV-I);(2) an HTLV-I infection endemic in the Caribbean, south-western Japan, South America and Africa.(3,4) Seroepidemiological studies suggest that it is also endemic in Brazil.(5) Although carriers of HTLV-I show polyclonal integration of virus in T lymphocytes, only patients with ATLL of various subtypes show monoclonal integration of HTLV-I in tumor cells.(6,7) Cutaneous T-cell lymphomas (CTCL) are a group of primary cutaneous lymphoproliferative diseases(8) with unknown etiology.(9) The two most common presentations of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS).(10-13) However, both CTCL categories can easily resemble ATLL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brazil. Cyclophosphamide / therapeutic use. DNA, Viral / analysis. Doxorubicin / therapeutic use. Endemic Diseases. Humans. Interferon-alpha / therapeutic use. Male. Neoplasm Recurrence, Local. Polymerase Chain Reaction. Prednisone / therapeutic use. Vincristine / therapeutic use. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16650175.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


74. Patkar N, Mehta J, Kulkarni B, Pande R, Advani S, Borges A: Immunoprofile of Hodgkin's lymphoma in India. Indian J Cancer; 2008 Apr-Jun;45(2):59-63
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of Hodgkin's lymphoma in India.
  • Large scale studies analyzing the immunoprofile of Hodgkin's lymphoma (HL) from India are lacking.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD15 / analysis. Antigens, CD20 / analysis. Antigens, CD30 / analysis. Child. Child, Preschool. Humans. Immunophenotyping. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626150.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30
  •  go-up   go-down


75. Gonzalez QH, Heslin MJ, Dávila-Cervantes A, Alvarez-Tostado J, de los Monteros AE, Shore G, Vickers SM: Primary colonic lymphoma. Am Surg; 2008 Mar;74(3):214-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colonic lymphoma.
  • Surgical resection of primary colonic lymphoma can be an important therapeutic tool.
  • From January 1990 to June 2002, a total of 15 patients with primary colonic lymphoma were identified from the tumor registry at University of Alabama at Birmingham and retrospectively reviewed under Institutional Review Board approved protocol.
  • Preoperative diagnosis of lymphoma was made in 13 patients (87%) with colonoscopy and biopsy.
  • According to the clinical classification of primary non-Hodgkin lymphoma (NHL) of the gastrointestinal tract (Lugano, 1993) all patients corresponded to stage IE.
  • Surgical resection of localized, primary colonic lymphoma provides excellent local disease control and should be considered a primary treatment option.
  • [MeSH-major] Colonic Neoplasms / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Colectomy / methods. Female. Humans. Length of Stay / statistics & numerical data. Male. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376684.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Blum YC, Esterhai JL, Esmail AN, Lackman RD, Donthineni-Rao R: Lymphoma masquerading as infection. Clin Orthop Relat Res; 2005 Mar;(432):267-71
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma masquerading as infection.
  • The cases of three patients with lymphoma that were treated as infectious processes are presented.
  • [MeSH-major] Bone Diseases, Infectious / diagnosis. Lymphoma / diagnosis. Soft Tissue Infections / diagnosis
  • [MeSH-minor] Adult. Biopsy / methods. Diagnosis, Differential. Female. Fractures, Spontaneous / diagnosis. Humans. Male. Middle Aged. Orthopedics / methods. Osteomyelitis / diagnosis. Shoulder. Staphylococcal Infections / diagnosis. Tibia. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738831.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Kenkre VP, Stock W: Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S231-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukemia: improving prognosis.
  • Burkitt lymphoma/leukemia (BL) has become a very curable mature B-cell neoplasm.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Child. Clinical Trials as Topic. Gene Expression Profiling. HIV Infections / complications. HIV Infections / drug therapy. Humans. Medical Oncology. Prognosis. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778846.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 47
  •  go-up   go-down


78. Ishitsuka K, Tamura K: Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol; 2008 Mar;80(3):185-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult T-cell leukemia/lymphoma: past, present, and future.
  • Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-cell lymphotrophic virus type I.
  • Clinical manifestations of ATLL range from smoldering to chronic, lymphoma and acute.
  • Patients with acute and lymphoma type ATLL require therapeutic intervention.
  • Conventional chemotherapeutic regimens used against other malignant lymphoma have been administered to ATLL patients, but the therapeutic outcomes of acute and lymphoma type ATLL remain very poor.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081707.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 157
  •  go-up   go-down


79. Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood; 2006 Jun 1;107(11):4500-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma.
  • Aggressive adult T-cell leukemia/lymphoma (ATLL) such as acute and lymphoma types are fatal diseases with poor prognosis.
  • We performed array-based comparative genomic hybridization for 17 acute and 49 lymphoma cases as well as real-time quantitative polymerase chain reaction (PCR) to identify the target genes of recurrently amplified regions.
  • Comparison of the genome profiles of acute and lymphoma types revealed that the lymphoma type had significantly more frequent gains at 1q, 2p, 4q, 7p, and 7q, and losses of 10p, 13q, 16q, and 18p, whereas the acute type showed a gain of 3/3p.
  • Of the recurrent high-level amplifications found at 1p36, 6p25, 7p22, 7q, and 14q32 in the lymphoma type, we were able to demonstrate that CARMA1 is a possible target gene of the 7p22 amplification for the lymphoma type but not for the acute type.
  • Furthermore, we found BCL11B overexpression in the acute type regardless of the 14q32 gain/amplification, but no or low expression of the gene in the lymphoma type.
  • These results suggest that acute and lymphoma types are genomically distinct subtypes, and thus may develop tumors via distinct genetic pathways.
  • [MeSH-major] Gene Amplification. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / genetics. CARD Signaling Adaptor Proteins. Chromosomes. DNA-Binding Proteins / genetics. Female. Gene Dosage. Gene Expression Regulation, Neoplastic. Guanylate Cyclase / genetics. Humans. Lymphoma / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Repressor Proteins / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484591.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BCL11B protein, human; 0 / CARD Signaling Adaptor Proteins; 0 / DNA-Binding Proteins; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


80. Vural F, Cagirgan S, Saydam G, Hekimgil M, Soyer NA, Tombuloglu M: Primary testicular lymphoma. J Natl Med Assoc; 2007 Nov;99(11):1277-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • We evaluated clinical features, management and survival of 12 patients with primary testicular non-Hodgkin's lymphoma presented to our hematology unit between January 1992 and July 2006, retrospectively.
  • Dominant histological subtype was diffuse large B-cell non-Hodgkin's lymphoma.
  • Because of the spreading nature and relapse probability at different sites, including central nervous system and contralateral testis, systemic treatment with doxorubicin-based chemotherapy with or without prophylaxis for contralateral testis and the central nervous system seems to improve the outcome of primary testicular lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Disease Progression. Doxorubicin. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Orchiectomy. Prednisone. Prognosis. Retrospective Studies. Survival. Treatment Outcome. Turkey. Vincristine

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2095-102 [7296517.001]
  • [Cites] Clin Radiol. 1981 Nov;32(6):687-92 [7307442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1699-703 [7153080.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):319-32 [16884838.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Oncology. 2004;67(3-4):211-4 [15557780.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):1-7 [9886690.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):59-62 [9020290.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur J Cancer. 1994;30A(1):1-3 [8142148.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):776-81 [3367185.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):297-302 [3339396.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1313-9 [11697846.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • (PMID = 18020104.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2574328
  •  go-up   go-down


81. Montravers F, de Bazelaire C, Kerrou K, Farges C, Huchet V, Talbot JN, Frija J, de Kerviler E: [Imaging and PET-CT of adult and childhood lymphoma]. J Radiol; 2008 Mar;89(3 Pt 2):371-84; quiz 385-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging and PET-CT of adult and childhood lymphoma].
  • Recently, PET has been integrated in the revised response criteria for malignant lymphoma.
  • [MeSH-major] Lymphoma / radiography. Lymphoma / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408639.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 48
  •  go-up   go-down


82. Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P: Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol; 2005 Sep;124(3):414-20
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
  • We retrospectively reviewed the immunophenotypic profile of 75 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) analyzed by flow cytometry.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Antigens, CD5 / analysis. Antigens, Neoplasm / analysis. Female. Glycoproteins / analysis. Humans. Immunophenotyping. Male. Middle Aged. Neprilysin / analysis. Receptors, IgE / analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16191510.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD5; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Receptors, IgE; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


83. Shtalrid M, Shvidel L, Korenfeld R, Duek A, Landau Z, Berrebi A: HTLV-1 associated adult T-cell leukemia/lymphoma in Israel: report of two patients of Romanian origin. Haematologica; 2005 Mar;90(3):ECR13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 associated adult T-cell leukemia/lymphoma in Israel: report of two patients of Romanian origin.
  • Human T-lymphotropic virus type 1 (HTLV-1) was the first human oncovirus isolated by Gallo et al. in 1980 and established as an etiological agent for adult T-cell leukemia/ lymphoma (ATL).
  • In Kyushu district, Japan, the seroprevalence reaches >30% in the adult population.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753054.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


84. Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Takeshita M, Suzumiya J, Utsunomiya A, Kikuchi M, Ohshima K: The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol; 2008 May;21(5):617-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma is an aggressive malignant disease associated with regulatory T cells as discussed in some recent reports.
  • We analyzed the expression of FOXP3, a key molecule of regulatory T cells, in adult T-cell leukemia/lymphoma and its association with clinicopathological features.
  • Of 169 adult T-cell leukemia/lymphoma cases examined, 60 (36%) showed FOXP3 expression in lymphoma cells.
  • FOXP3 expression in adult T-cell leukemia/lymphoma thus reflects morphological features and is clinically and pathologically associated with an immunosuppressive state.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Southern. Epstein-Barr Virus Infections / metabolism. Female. Herpesvirus 4, Human. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246047.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


85. Yamada Y, Kamihira S: Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1553-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.
  • Almost three decades have passed since adult T-cell leukemia-lymphoma (ATLL) was proposed as a new disease entity.
  • [MeSH-major] Gene Silencing. Genes, Tumor Suppressor. Leukemia-Lymphoma, Adult T-Cell / etiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236609.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


86. Yamaguchi T, Ohshima K, Karube K, Tutiya T, Kawano R, Suefuji H, Shimizu A, Nakayama J, Suzumiya J, Moroi Y, Urabe K, Furue M, Koga T, Kikuchi M: Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma. Br J Dermatol; 2005 Jan;152(1):76-81
Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of cutaneous lesions of adult T-cell leukaemia/ lymphoma.
  • BACKGROUND: Adult T-cell leukaemia/lymphoma (ATLL) is a human malignancy associated with human T-cell leukaemia virus type I (HTLV-I).
  • Histopathologically, the prognosis was poorer in patients with nodular or diffuse infiltration of medium-sized to large lymphoma cells, compared with those with perivascular infiltration of small to medium-sized lymphoma cells.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Skin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / analysis. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Male. Middle Aged. Prognosis. Proviruses / isolation & purification. Survival Analysis. Virus Integration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656804.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


87. Massini G, Siemer D, Hohaus S: EBV in Hodgkin Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV in Hodgkin Lymphoma.
  • Up to 40% of Hodgkin lymphoma (HL) cases are associated with the Epstein-Barr virus (EBV).
  • The presence of EBV in HL is associated with several clinicopathological characteristics: It is more frequent in cases with mixed cellular histology, in males, in children and older adults, and in developing countries, while the young-adult onset HL of nodular sclerosis type in industrialized countries is typically EBV-negative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Dec 15;106(13):4345-50 [16131568.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):460-4 [16428487.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1650-5 [16983344.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1315-21 [16923562.001]
  • [Cites] Cancer Lett. 2008 Oct 18;270(1):66-76 [18539384.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1499-507 [18646185.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):537-48 [19017178.001]
  • [Cites] J Infect Dis. 1979 May;139(5):553-8 [220340.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):929-31 [2594086.001]
  • [Cites] J Infect Dis. 1971 Mar;123(3):263-70 [4329526.001]
  • [Cites] J Infect Dis. 1973 Apr;127(4):471-3 [4348499.001]
  • [Cites] Wistar Inst Symp Monogr. 1965 Sep;4:69-82 [5884338.001]
  • [Cites] Arch Virol. 1998;143(4):803-13 [9638150.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] J Pathol. 1999 Feb;187(3):326-30 [10398087.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4249-52 [16123211.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Ann Hematol. 2006 Jul;85(7):463-8 [16534596.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;310:61-80 [16909907.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1376-81 [17496310.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5771-8 [17575144.001]
  • [Cites] J Virol. 2007 Sep;81(18):10092-100 [17626071.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3310-5 [17630352.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1470-4 [18024394.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1342-9 [18042690.001]
  • [Cites] J Immunol. 2007 Dec 15;179(12):8225-34 [18056366.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):716-9 [18470916.001]
  • [Cites] Virology. 1991 Apr;181(2):595-608 [1849678.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1769-77 [18661399.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6974-8 [18980992.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Leuk Res. 2009 Oct;33(10):1352-6 [19201467.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):976-86 [19223558.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3815-21 [19470931.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1495-505 [8879220.001]
  • [Cites] J Virol. 1997 Jul;71(7):4882-91 [9188550.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1664-72 [9269787.001]
  • [Cites] J Pathol. 1997 Jul;182(3):299-306 [9349232.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6959-64 [10602470.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1522-8 [10995808.001]
  • [Cites] Immunity. 2000 Oct;13(4):485-95 [11070167.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2080-4 [11280769.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1579-87 [11301409.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1227-34 [11336475.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3964-73 [11359904.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Curr Oncol Rep. 2000 Mar;2(2):199-204 [11122844.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):360-7 [11555713.001]
  • [Cites] Eur J Cancer. 2001 Oct;37(15):1853-7 [11576839.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):259-64 [12209977.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):282-90 [12562657.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):159-65 [14530808.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3060-2 [11929801.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:23-9 [12078898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Nat Med. 2003 Mar;9(3):307-14 [12592401.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Virol. 2000 Nov;74(22):10468-79 [11044091.001]
  • [Cites] J Pathol. 2003 Nov;201(3):413-20 [14595753.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):811-6 [14600123.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):331-6 [15242681.001]
  • [Cites] J Pathol. 2005 May;206(1):68-75 [15751051.001]
  • [Cites] Br J Haematol. 2005 May;129(4):511-9 [15877733.001]
  • [Cites] Saudi Med J. 2005 Apr;26(4):571-5 [15900362.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1807-14 [11696441.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1324-32 [14523140.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Clin Immunol. 2003 Oct;109(1):53-63 [14585276.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):442-7 [17390376.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1326-9 [17438085.001]
  • [Cites] J Virol. 1995 Jun;69(6):3752-8 [7745723.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1360-6 [7882287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Int J Cancer. 1993 Sep 30;55(3):359-63 [8397160.001]
  • [Cites] Mod Pathol. 1995 Aug;8(6):675-9 [8532705.001]
  • [Cites] Arch Dis Child. 1996 Jan;74(1):27-31 [8660041.001]
  • [Cites] Immunity. 1996 Aug;5(2):173-9 [8769480.001]
  • [Cites] Int J Cancer. 1997 Apr 10;71(2):138-41 [9139832.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Cell. 1979 Jul;17(3):661-71 [225039.001]
  • [Cites] N Engl J Med. 1989 Feb 23;320(8):502-6 [2536894.001]
  • [Cites] J Exp Med. 1988 Dec 1;168(6):2059-75 [2848918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101 [5242134.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2447-51 [7919364.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Blood. 1993 Jan 15;81(2):496-501 [8380728.001]
  • [Cites] Int J Cancer. 1996 Mar 15;65(6):781-4 [8631592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 [14688409.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6611-6 [15096587.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2138-46 [15933052.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4048-56 [15961758.001]
  • [Cites] Lancet. 2005 Jun 25-Jul 1;365(9478):2216-24 [15978930.001]
  • [Cites] J Allergy Clin Immunol. 2005 Aug;116(2):251-61; quiz 262 [16083776.001]
  • (PMID = 21416003.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033177
  •  go-up   go-down


88. Chaar BT, Salem P, Petruska PJ: Procarbazine for non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Apr;47(4):637-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine for non-Hodgkin's lymphoma.
  • Procarbazine hydrochloride is an oral alkylating agent with activity against lymphoma.
  • The use of procarbazine-containing chemotherapeutic regimens in non-Hodgkin's lymphoma fell out of favor with the advent of CHOP.
  • We report two patients with relapsed and/or refractory follicular lymphoma that achieved a complete and durable remission with a prolonged course of daily procarbazine.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Procarbazine / therapeutic use
  • [MeSH-minor] Adult. Alkylating Agents / therapeutic use. Antineoplastic Agents / pharmacology. Enzyme Inhibitors / pharmacology. Female. Humans. Male. Middle Aged. Monoamine Oxidase Inhibitors / pharmacology. Remission Induction. Stem Cell Transplantation / methods

  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690522.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Monoamine Oxidase Inhibitors; 35S93Y190K / Procarbazine
  •  go-up   go-down


89. Nieters A, Deeg E, Becker N: Tobacco and alcohol consumption and risk of lymphoma: results of a population-based case-control study in Germany. Int J Cancer; 2006 Jan 15;118(2):422-30
MedlinePlus Health Information. consumer health - Smoking and Youth.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco and alcohol consumption and risk of lymphoma: results of a population-based case-control study in Germany.
  • Changing trends in lifestyle exposures are suggested to be contributing factors to the increasing incidence rates for lymphoma.
  • We investigated the relationship between smoking and alcohol consumption and the risk of lymphoma among adult participants of a population-based case-control study recently conducted in Germany.
  • In 710 case-control pairs, an increased risk of lymphoma was associated with a long duration of smoking (p for trend = 0.01 for men) and smoking of > 20 cigarettes per day(OR = 2.7; 95% CI = 1.4-5.2 for women).
  • Elevated odds ratios were seen for most lymphoma subentities, albeit mostly without reaching statistical significance.
  • A strong association was evident between smoking and multiple myeloma (OR = 2.4, 95% CI = 0.98-5.74 for men; OR = 2.9, 95% CI = 1.1-7.4 for women) and Hodgkin's lymphoma among men (OR = 3.6; 95% CI = 1.7-7.5).
  • Alcohol consumption 10 years prior to the date of interview appeared to decrease the risk of lymphoma.
  • Although biologic rationale for a protective effect of alcohol consumption may be given, a more in-depth analysis involving genetic markers is indicated to clarify if ethanol, other components in alcoholic beverages, or factors associated with moderate drinking reduce lymphoma risk among adults.
  • In conclusion, this investigation suggests a positive association between tobacco smoking and lymphoma risk and finds decreased odds ratios among consumers of alcohol.
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Germany / epidemiology. Humans. Life Style. Male. Middle Aged. Odds Ratio. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16080191.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Owatari S, Otsuka M, Uozumi K, Takeshita T, Hanada S: Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma. Int J Hematol; 2007 Jan;85(1):32-5
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma.
  • We identified 2 cases of secondary acute myeloid leukemia (AML) following adult T-cell leukemia/lymphoma (ATL) in patients who had previously received chemotherapy.
  • In our hospital, only these 2 cases of secondary AML accompanying ATL were identified among 90 cases of acute- or lymphoma-type ATL diagnosed from October 1999 to July 2006.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid / chemically induced. Leukemia-Lymphoma, Adult T-Cell / complications. Neoplasms, Second Primary / chemically induced

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261499.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


91. Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S: Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett; 2006 Mar 28;234(2):249-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma.
  • Based on statistical analysis of its age-dependent occurrence, a multi-step carcinogenesis model has been proposed for Adult T-cell Leukemia/Lymphoma (ATLL).
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Aberrations. Genes, p16. Genes, p53. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Polymorphism, Single-Stranded Conformational. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896902.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


92. Shimakage M, Inoue N, Ohshima K, Kawahara K, Oka T, Yasui K, Matsumoto K, Inoue H, Watari A, Higashiyama S, Yutsudo M: Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma. Int J Cancer; 2006 Oct 1;119(7):1648-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma.
  • [MeSH-major] Down-Regulation / genetics. Gene Expression Regulation, Neoplastic / genetics. Intracellular Signaling Peptides and Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Membrane Proteins / genetics. Myelin Proteins / genetics. Transcription, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Gene Products, tax / genetics. Humans. Male. Middle Aged. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16646068.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Myelin Proteins; 0 / Nogo protein; 0 / RNA, Messenger
  •  go-up   go-down


93. Faris M: Potential for molecular targeted therapy for adult T-cell leukemia/lymphoma. Int Rev Immunol; 2008 Jan-Apr;27(1-2):71-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential for molecular targeted therapy for adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma is an aggressive lymphoproliferative disorder of CD4+ T lymphocytes associated with human T-cell leukemia virus type 1 (HTLV-I) infection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300056.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Basic-Leucine Zipper Transcription Factors; 0 / Cytokines; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Viral Proteins
  • [Number-of-references] 28
  •  go-up   go-down


94. Yasunami T, Wang YH, Tsuji K, Takanashi M, Yamada Y, Motoji T: Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res; 2007 Apr;31(4):465-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.
  • In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins.
  • [MeSH-major] Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134750.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


95. Mohindra S, Gupta R, Sharma T, Das A, Radotra BD: Calvarial lymphoma. Br J Neurosurg; 2007 Dec;21(6):629-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calvarial lymphoma.
  • [MeSH-major] Dura Mater / radiography. Lymphoma, B-Cell / radiography. Meningeal Neoplasms / radiography. Meningioma / radiography. Skull Neoplasms / radiography
  • [MeSH-minor] Adult. Craniotomy / methods. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071996.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Okada J, Imafuku S, Tsujita J, Moroi Y, Urabe K, Furue M: Case of adult T-cell leukemia/lymphoma manifesting marked purpura. J Dermatol; 2007 Nov;34(11):782-5
MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of adult T-cell leukemia/lymphoma manifesting marked purpura.
  • We therefore diagnosed this case as adult T-cell leukemia/lymphoma (ATL), and the purpuric lesions as ATL-specific.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Pigmentation Disorders / etiology. Purpura / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973821.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Jaglowski SM, Linden E, Termuhlen AM, Flynn JM: Lymphoma in adolescents and young adults. Semin Oncol; 2009 Oct;36(5):381-418
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma in adolescents and young adults.
  • Non-Hodgkin (NHL) and Hodgkin (HL) lymphomas are represented prominently in the adolescent and young adult (AYA) population.
  • Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma make up the most common subtypes in the AYA population, although within the subgroup age 30-39 years, follicular lymphoma becomes more prominent.
  • [MeSH-major] Lymphoma
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Male. Neoplasm Staging. Prevalence. Prognosis. SEER Program. United States / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835736.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 239
  •  go-up   go-down


98. Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, Tomonaga M, Tsukasaki K: Long-term study of indolent adult T-cell leukemia-lymphoma. Blood; 2010 Jun 3;115(22):4337-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term study of indolent adult T-cell leukemia-lymphoma.
  • The long-term prognosis of indolent adult T-cell leukemia-lymphoma (ATL) is not clearly elucidated.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348391.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Koga Y, Iwanaga M, Soda M, Inokuchi N, Sasaki D, Hasegawa H, Yanagihara K, Yamaguchi K, Kamihira S, Yamada Y: Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. J Med Virol; 2010 Apr;82(4):668-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan.
  • The incidence of adult T-cell leukemia/lymphoma (ATLL) among HTLV-1 carriers was estimated using data from the Nagasaki Prefectural Cancer Registry.
  • [MeSH-major] HTLV-I Infections / complications. HTLV-I Infections / epidemiology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State / epidemiology. Child. Child, Preschool. Female. Hospitals. Humans. Incidence. Infant. Infant, Newborn. Japan. Male. Middle Aged. Seroepidemiologic Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20166187.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Hidaka T, Nakahata S, Hatakeyama K, Hamasaki M, Yamashita K, Kohno T, Arai Y, Taki T, Nishida K, Okayama A, Asada Y, Yamaguchi R, Tsubouchi H, Yokota J, Taniwaki M, Higashi Y, Morishita K: Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood; 2008 Jul 15;112(2):383-93
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by latent human T-lymphotropic virus-1 (HTLV-1) infection.
  • [MeSH-major] Homeodomain Proteins / physiology. Leukemia-Lymphoma, Adult T-Cell / etiology. Transcription Factors / physiology. Transforming Growth Factor beta1 / physiology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467597.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / ZEB1 protein, human
  •  go-up   go-down






Advertisement